Harvard Bioscience (NASDAQ:HBIO) Stock Rating Lowered by Wall Street Zen

Harvard Bioscience (NASDAQ:HBIO) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

Other equities analysts have also issued reports about the stock. Benchmark decreased their target price on shares of Harvard Bioscience from $20.00 to $6.00 and set a “speculative buy” rating on the stock in a report on Friday, March 13th. New Street Research set a $6.00 price target on shares of Harvard Bioscience in a report on Friday, March 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Harvard Bioscience in a research report on Monday, December 29th. Finally, Zacks Research raised shares of Harvard Bioscience to a “hold” rating in a research note on Thursday, December 11th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $6.00.

Harvard Bioscience Stock Performance

HBIO opened at $5.27 on Friday. The company has a debt-to-equity ratio of 2.61, a quick ratio of 1.25 and a current ratio of 2.20. Harvard Bioscience has a 52-week low of $2.81 and a 52-week high of $9.50. The firm has a market cap of $23.57 million, a P/E ratio of -0.41 and a beta of 1.51. The business’s fifty day moving average is $5.55 and its 200-day moving average is $5.67.

Insiders Place Their Bets

In other Harvard Bioscience news, Director Stephen J. Denelsky bought 10,000 shares of the stock in a transaction on Tuesday, March 17th. The stock was purchased at an average price of $4.87 per share, with a total value of $48,700.00. Following the completion of the purchase, the director owned 21,000 shares in the company, valued at $102,270. The trade was a 90.91% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director William Snider bought 12,525 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was bought at an average cost of $4.99 per share, with a total value of $62,499.75. Following the acquisition, the director directly owned 23,525 shares of the company’s stock, valued at approximately $117,389.75. The trade was a 113.86% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders acquired 36,000 shares of company stock valued at $177,354. 20.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Harvard Bioscience

Several institutional investors and hedge funds have recently added to or reduced their stakes in HBIO. Weber Capital Management LLC ADV bought a new stake in shares of Harvard Bioscience during the fourth quarter worth $2,140,000. Corsair Capital Management L.P. lifted its stake in shares of Harvard Bioscience by 1,008.7% in the 4th quarter. Corsair Capital Management L.P. now owns 1,108,692 shares of the medical instruments supplier’s stock valued at $741,000 after acquiring an additional 1,008,692 shares during the last quarter. Nano Cap New Millennium Growth Fund L P bought a new position in shares of Harvard Bioscience in the 4th quarter valued at $401,000. AMH Equity Ltd boosted its holdings in shares of Harvard Bioscience by 15.4% during the 3rd quarter. AMH Equity Ltd now owns 4,047,535 shares of the medical instruments supplier’s stock valued at $1,775,000 after acquiring an additional 538,832 shares in the last quarter. Finally, Meros Investment Management LP boosted its holdings in shares of Harvard Bioscience by 32.6% during the 4th quarter. Meros Investment Management LP now owns 1,217,628 shares of the medical instruments supplier’s stock valued at $814,000 after acquiring an additional 299,369 shares in the last quarter. Institutional investors own 80.87% of the company’s stock.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.